ISRG Stock Gets A Barrage Of Price Target Cuts From Wall Street — Citi Removes It From ‘Upside 90-Day Catalyst Watch’

• Intuitive reported earnings per share (EPS) of $2.8 in the second quarter, compared to the analysts’ estimate of $2.51. 
• Revenue jumped 19% year-over-year to $2.89 billion versus the estimated $2.82 billion.
• JPMorgan noted that the company's in-line procedures and reiterated guidance overshadow the "healthy" da Vinci placements and "robust" profitability.

Shares of Intuitive (ISRG) tumbled over 10% and were on track to hit their 30-month lows in Friday’s premarket after the company reported its second-quarter (Q2) results.

The stock also received a barrage of price target cuts on Friday, with the new target ranging from $400 to $685. As of this writing, the stock traded near the $359 level in Friday’s opening trade.

ISRG’s Q2 At A Glance

Intuitive reported earnings per share (EPS) of $2.8, compared to the analysts’ estimate of $2.51. Revenue jumped 19% year-over-year to $2.89 billion versus the estimated $2.82 billion.

During the first-quarter (Q1) earnings announcement, the company had highlighted that it expects Worldwide da Vinci procedure growth of approximately 13.5% to 15.5% in 2026. During the Q2 report, Intuitive said it now expects the figure to be closer to the midpoint of this range.

Meanwhile, Intuitive’s Worldwide procedures rose approximately 16% compared with the second quarter of 2025. Da Vinci procedures grew nearly 15%, and Ion procedures grew approximately 36%.

The firm’s da Vinci surgical system installed base grew 12% to 11,710 systems in Q2, while the Ion endoluminal system installed base rose 21% to 1,096 systems.

Wall Street’s Take On ISRG

According to TheFly, Citi lowered its price target to $500 from $590 and keeps a ‘Buy’ rating. The firm removed its "upside 90-day catalyst watch" on Intuitive Surgical. The analyst noted that Affordable Care Act headwinds are making management incrementally conservative on procedures, which is weighing on the shares in the near term.

Mizuho lowered its target to $400 from $500, while keeping a ‘Neutral’ rating on the shares. It noted that the company's systems strength was offset by in-line performances across instruments and accessories, which were linked to a slowdown in da Vinci procedures.

Meanwhile, Bernstein slashed its price target to $685 from $750, while maintaining an ‘Outperform’ rating on the shares. The firm believes concerns about the U.S. procedure growth trend will ignite debates and weigh on the stock, especially as the third quarter (Q3) approaches.

JPMorgan lowered its target to $450 from $550 and kept an ‘Overweight’ rating on the shares. It noted that the company's in-line procedures and reiterated guidance overshadow the "healthy" da Vinci placements and "robust" profitability.

What Retail Thinks Of ISRG

Retail sentiment on Stocktwits surrounding ISRG rose to ‘extremely bullish’ territory from ‘bullish’ a day ago.

One user on the platform expressed their bullish take on the stock, saying it’s an opportunity of a lifetime.

ISRG shares have lost over 28% this year.

Read Also: NFLX Stock Headed For Worst Single-Day Fall In 9 Months On Weak Q3 Guidance — Analyst Warns Netflix Is 'Losing Narrative Control'

For updates and corrections, email newsroom[at]stocktwits[dot]com.